PHASE IB/II CLINICAL TRIAL OF ALPELISIB AND TUCATINIB IN PATIENTS WITH PIK3CA-MUTANT HER2-POSITIVE METASTATIC BREAST CANCER
Details
Age
Adult
Type of Study
Treatment
Scope
National
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Elena Shagisultanova, MD, PhD
Study ID
Protocol Number: 21-5033
More information available at ClinicalTrials.gov: NCT05230810
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers